by The Preimplantation Genetic Diagnosis (PGD) Market is estimated to be valued at US$ 64.08 Mn or Mn in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Preimplantation genetic diagnosis (PGD) is a medical procedure used prior to implantation during in vitro fertilization (IVF). PGD is used to identify genetic defects in embryos before implantation and pregnancy. It allows genetic screening of embryos created through IVF, for hereditary diseases, chromosomal abnormalities like trisomy 13, trisomy 18, trisomy 21, and monogenic diseases like cystic fibrosis and muscular dystrophy. PGD reduces the risk that a genetically abnormal embryo will be transferred during IVF and has potential for the selection of unaffected embryos without inherited diseases or chromosomal abnormalities.
Market Dynamics:
The preimplantation genetic diagnosis market is driven by the increasing incidence of genetic disorders and rising infertility rates globally. As per the World Health Organization (WHO), around 48.5 million couples worldwide are suffering from infertility. In addition, advanced maternal age, obesity, sexually transmitted diseases, genetic disorders, diabetes, and lifestyle factors are major contributors for infertility. Thus, increasing cases of infertility and genetic disorders are anticipated to boost the demand for preimplantation genetic diagnosis procedures over the forecast period. Furthermore, improving healthcare infrastructure, rising medical tourism, and growing awareness regarding treatment of genetic disorders are also expected to propel the market growth. However, high procedural costs and lack of accessibility to treatment in developing countries may hamper the market growth.
Segment Analysis
The preimplantation genetic diagnosis (PGD) market can be segmented based on product into equipment, reagents and consumables, and software & services. Among these, the reagents and consumables segment is dominating the preimplantation genetic diagnosis (PGD) market currently. This is owing to the recurring use of reagents and consumables for each PGD procedure, unlike the equipment which is a one-time investment.
PEST Analysis
Political: Regulations regarding genetic screening are well defined in many parts of the world which is encouraging the growth of the PGD market. However, lack of regulations in some regions is still hindering complete market potential.
Economic: Rising awareness about genetic disorders and increasing health expenditure is fueling the demand for PGD procedures worldwide. However, high cost associated with these tests can limit market growth to some extent.
Social: Higher acceptance towards pre-natal screening for genetic conditions is driving the adoption of PGD procedures. However, ethical concerns regarding embryo selection and destruction limits market prospects to some degree.
Technological: Advancements in genetic screening methods like Next-Generation Sequencing (NGS) and development of rapid and accurate tests are supporting the growth of the PGD market.
Key Takeaways
The global Preimplantation Genetic Diagnosis Market Growth is expected to witness high growth, exhibiting CAGR of 6.2% over the forecast period, due to increasing prevalence of genetic disorders and rising focus on pre-pregnancy screening. North America dominated the regional analysis currently owing to supportive regulatory environment and availability of advanced healthcare facilities in the region. Key players operating in the preimplantation genetic diagnosis (PGD) market are Amgen, Quest Diagnostics, Genentech Inc., Vertex, PerkinElmer, Inc., F. Hoffman-La-Roche Ltd, Thermo Fisher Scientific, Inc., and Laboratory Corporation of America Holdings, Abbott Laboratories, Illumina, Inc., Natera Inc., CooperGenomics Inc., Reproductive Genetics Institute, Inc., Genea Ltd., Invitae Corporation, and CombiMatrix Corporation.
Regional analysis shows that Asia Pacific region is expected to witness fastest growth during the forecast period due to improving healthcare infrastructure, rising medical tourism, and growing focus of international players focusing on emerging Asia Pacific markets. Key players in the preimplantation genetic diagnosis (PGD) market are focusing on product launches and collaboration with IVF centers to strengthen their presence. For instance, in 2021, Natera collaborated with The Fertility Partners to offer PGD testing to identify genetic disorders.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
